Sales in Q1 was higher than we expected due to strong sales in primarily Health & Wellness, but also in accessories and audio. Health & wellness and online sales contributed to a low gross margin, which resulted in a weaker than expected EBITDA. Covid is a waiting game for Strax and we believe the low valuation in combination with two triggers create a good opportunity. We maintain our valuation.